PMID- 29879928 OWN - NLM STAT- MEDLINE DCOM- 20190125 LR - 20231112 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 18 IP - 1 DP - 2018 Jun 7 TI - Comparison of hepatic resection and transarterial chemoembolization for UICC stage T3 hepatocellular carcinoma: a propensity score matching study. PG - 643 LID - 10.1186/s12885-018-4557-5 [doi] LID - 643 AB - BACKGROUND: The optimal therapeutic strategy in UICC stage T3 hepatocellular carcinoma (HCC) patients that maximizes both safety and long-term outcome has not yet been determined. Our aim was to compare clinical outcomes following hepatic resection (HR) versus transarterial chemoembolization (TACE) for stage T3 HCC. METHODS: From 2005 to 2013, 1179 patients with T3 HCC who underwent HR or TACE were divided into two groups, HR group (n = 280) or TACE group (n = 899). The clinical outcomes were compared before and after propensity score matching. RESULTS: The propensity model matched 244 patients in each group for further analyses. After matching, medium overall survival (OS), 1, 3, and 5-year OS rates in TACE group were 11.8 (95%CI, 9.9-13.7) months, 49.6, 16.5, and 8.4%, respectively; which in HR group were 17.8 (95% CI, 14.8-20.8) months, 63.1, 33.3, and 26.4%, respectively; (log rank = 19.908, P < 0.01). Patients in HR group were more likely to develop pleural effusion, compared with those in TACE group (0.4% vs. 5.3%, P = 0.01). However, no significant differences in other adverse events (AEs) were found between two groups. Similar results were also demonstrated prior to the matched analysis. Multivariate analysis indicated that prothrombin time (PT), tumor size, tumor numbers, UICC staging status, and initial treatment were independent prognostic factors. CONCLUSIONS: Our study revealed that TACE was an option for UICC T3 HCC patients. However, HR seemed to be safe and yield a survival benefit compared with TACE, especially for patients with a good underlying liver function. FAU - Zhong, Chong AU - Zhong C AUID- ORCID: 0000-0003-4199-0509 AD - Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, 16 Airport Road, Guangzhou, 510405, China. sumszhong@yahoo.com. AD - Department of Hepatobiliary Surgery, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, 16 Airport Road, Guangzhou, 510405, China. sumszhong@yahoo.com. FAU - Zhang, Yong-Fa AU - Zhang YF AD - Department of Liver Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. AD - Department of Hepatobiliary Oncology, Cancer Center of Sun Yat-sen University, Guangzhou, 510060, China. FAU - Huang, Jun-Hai AU - Huang JH AD - Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, 16 Airport Road, Guangzhou, 510405, China. AD - Department of Hepatobiliary Surgery, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, 16 Airport Road, Guangzhou, 510405, China. FAU - Xiong, Cheng-Ming AU - Xiong CM AD - The First Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. FAU - Wang, Zi-Yu AU - Wang ZY AD - The First Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. FAU - Chen, Qing-Lian AU - Chen QL AD - The First Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. FAU - Guo, Rong-Ping AU - Guo RP AD - Department of Hepatobiliary Oncology, Cancer Center of Sun Yat-sen University, Guangzhou, 510060, China. guorp@sysucc.org.cn. LA - eng GR - 81403397/National Natural Science Foundation of China/ GR - 2014A030313408/Natural Science Foundation of Guangdong Province/ GR - 2016A020226052/Guangdong Science and Technology Department/ PT - Comparative Study PT - Journal Article DEP - 20180607 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Adult MH - Carcinoma, Hepatocellular/mortality/pathology/*therapy MH - Chemoembolization, Therapeutic/adverse effects/*methods MH - Female MH - Hepatectomy/adverse effects/*methods MH - Humans MH - Liver Neoplasms/mortality/pathology/*therapy MH - Male MH - Middle Aged MH - Propensity Score MH - Survival Analysis MH - Treatment Outcome PMC - PMC5992633 OTO - NOTNLM OT - Hepatic resection OT - Hepatocellular carcinoma OT - Propensity score matching study OT - TACE COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The study protocol was approved by the Ethics Committee of Sun Yat-Sen University Cancer Center and The First Affiliated Hospital of Guangzhou University of Chinese Medicine. All recruited patients provided written informed consent before treatment. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2018/06/09 06:00 MHDA- 2019/01/27 06:00 PMCR- 2018/06/07 CRDT- 2018/06/09 06:00 PHST- 2017/10/31 00:00 [received] PHST- 2018/05/28 00:00 [accepted] PHST- 2018/06/09 06:00 [entrez] PHST- 2018/06/09 06:00 [pubmed] PHST- 2019/01/27 06:00 [medline] PHST- 2018/06/07 00:00 [pmc-release] AID - 10.1186/s12885-018-4557-5 [pii] AID - 4557 [pii] AID - 10.1186/s12885-018-4557-5 [doi] PST - epublish SO - BMC Cancer. 2018 Jun 7;18(1):643. doi: 10.1186/s12885-018-4557-5.